Buspirone/Carbidopa/Levodopa

丁螺环酮/卡比多巴/左旋多巴

Report date: 2022/01/14 13:23:58

Base Information

Drug NameBuspirone/Carbidopa/Levodopa
Drug Alias NameCarbidopa+Levodopa+Buspirone卡比多巴+左旋多巴+丁螺环酮卡比多巴/左旋多巴/丁螺环酮Carbidopa/Levodopa/Buspirone丁螺环酮/左旋多巴/卡比多巴 +[11] 
ClassificationSmall molecules
Mechanisms of ActionSerotonin 1a (5-HT1a) receptor partial agonistsDopamine receptors agonistsDOPA decarboxylase inhibitors +[4] 
TargetsAromatic-L-amino-acid decarboxylaseDopamine receptorsSerotonin 1a (5-HT1a) receptor +[4] 
Therapy Area/IndicationsSpinal Cord InjuriesMultiple Sclerosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsYes Buspirone HydrochlorideLevodopaCarbidopa
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesUniversite Laval
China Registration ClassN/A

Develop Information

Active CompaniesNational Institutes Of HealthUniversite LavalNordic Life Science Pipeline Inc
Inactive CompaniesN/A
Active IndicationsSpinal Cord InjuriesMultiple Sclerosis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A